Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

by Zacks Equity Research

Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

    AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

    by Zacks Equity Research

    AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

      Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

      by Zacks Equity Research

      Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

        Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

        by Zacks Equity Research

        Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

          Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

          by Zacks Equity Research

          Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

            Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

            by Zacks Equity Research

            FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

              Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline

              by Zacks Equity Research

              Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.

                Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

                by Zacks Equity Research

                The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

                  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

                  by Zacks Equity Research

                  Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

                    Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down

                    by Zacks Equity Research

                    Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.

                      Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss

                      by Zacks Equity Research

                      Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.

                        Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

                        by Zacks Equity Research

                        Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

                          Ekta Bagri headshot

                          Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View

                          by Ekta Bagri

                          Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.

                            Ekta Bagri headshot

                            Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

                            by Ekta Bagri

                            Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

                              Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses

                              by Zacks Equity Research

                              Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.

                                VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

                                by Zacks Equity Research

                                VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

                                  Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

                                  by Zacks Equity Research

                                  Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.

                                    Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

                                    by Zacks Equity Research

                                    Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.

                                      Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1

                                      by Zacks Equity Research

                                      Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.

                                        Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View

                                        by Zacks Equity Research

                                        Ligand (LGND) beats both earnings and sales estimates in the first quarter of 2018. The company repeats its previous guidance for 2018.

                                          Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y

                                          by Zacks Equity Research

                                          Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.

                                            AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

                                            by Zacks Equity Research

                                            AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.

                                              Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1

                                              by Zacks Equity Research

                                              Merrimack (MACK) reports wider-than-expected loss in the first quarter.

                                                Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected

                                                by Zacks Equity Research

                                                Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.

                                                  Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates

                                                  by Zacks Equity Research

                                                  Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.